Schrijver Iris, Lay Marla J, Zehnder James L
Department of Pathology, Molecular Pathology Laboratory, Stanford University Medical Center, Stanford, CA 94305, USA.
Am J Clin Pathol. 2003 Apr;119(4):490-6. doi: 10.1309/3VTR-7TL2-X7TX-L0QY.
Genetic thrombosis risk factors include a sequence variant in the prothrombin gene (20210G > A) and factor V Leiden (1691G > A). These single nucleotide polymorphisms can be diagnosed with restriction fragment length polymorphism (RFLP) analysis, fluorescent genotyping on the LightCycler (Roche Diagnostics, Indianapolis, IN), and microarray-based testing on the novel NanoChip electronic microarray (NanoChip Molecular Biology Workstation, Nanogen, San Diego, CA). We compared these methods for accuracy, time to results, throughput, and interpretation. Results from 789 of 800 individual amplicons analyzed on the NanoChip were in complete agreement with the other assays. Eleven were "no calls" (uninterpreted by the NanoChip system) resulting from failed polymerase chain reaction amplifications. Although the NanoChip System, when used in a low-throughput setting, requires more overall time than the LightCycler, it is nearly equivalent per genotyping call. Owing to minimal sample handling, assay results are more reliable on the NanoChip platform and on the LightCycler than with RFLP. The NanoChip assay is reliable and may be especially valuable to laboratories with a large volume of thrombophilia test requests.
遗传性血栓形成风险因素包括凝血酶原基因的一个序列变异(20210G>A)和因子V莱顿突变(1691G>A)。这些单核苷酸多态性可通过限制性片段长度多态性(RFLP)分析、LightCycler(罗氏诊断公司,印第安纳波利斯,印第安纳州)上的荧光基因分型以及新型NanoChip电子微阵列(NanoChip分子生物学工作站,Nanogen公司,圣地亚哥,加利福尼亚州)上基于微阵列的检测来诊断。我们比较了这些方法在准确性、出结果时间、通量和判读方面的情况。在NanoChip上分析的800个个体扩增子中有789个的结果与其他检测完全一致。11个因聚合酶链反应扩增失败而“无结果”(未被NanoChip系统判读)。虽然NanoChip系统在低通量设置下使用时,总体所需时间比LightCycler长,但每次基因分型检测的时间几乎相当。由于样本处理最少,NanoChip平台和LightCycler上的检测结果比RFLP更可靠。NanoChip检测是可靠的,对于有大量血栓形成倾向检测需求的实验室可能特别有价值。